MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia

Jon Kerry, Laura Godfrey, Emmanouela Repapi, Marta Tapia, Neil P. Blackledge, Helen Ma, Erica Ballabio, Sorcha O'Byrne, Frida Ponthan, Olaf Heidenreich, Anindita Roy, Irene Roberts, Marina Konopleva, Robert J. Klose, Huimin Geng, Thomas A. Milne

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

50 Citaten (Scopus)

Samenvatting

Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find that at a subset of gene targets, MLL-AF4 binding spreads into the gene body and is associated with the spreading of Menin binding, increased transcription, increased H3K79 methylation (H3K79me2/3), a disruption of normal H3K36me3 patterns, and unmethylated CpG regions in the gene body. Compared to other H3K79me2/3 marked genes, MLL-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L. This sensitivity mediates synergistic interactions with additional targeted drug treatments. Therefore, epigenetic spreading and enhanced susceptibility to epidrugs provides a potential marker for better understanding combination therapies in humans.

Originele taal-2Engels
Pagina's (van-tot)482-495
Aantal pagina's14
TijdschriftCell Reports
Volume18
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - 10 jan. 2017
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit